Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 3
1975 2
1976 2
1983 2
1985 3
1986 1
1987 1
1990 1
1992 2
1993 1
1994 4
1995 6
1996 3
1997 4
1998 5
1999 9
2000 17
2001 19
2002 35
2003 21
2004 39
2005 37
2006 47
2007 45
2008 40
2009 30
2010 36
2011 60
2012 61
2013 64
2014 62
2015 68
2016 53
2017 47
2018 68
2019 54
2020 70
2021 58
2022 19
Text availability
Article attribute
Article type
Publication date

Search Results

1,006 results
Results by year
Filters applied: . Clear all
Page 1
A novel era of cancer/testis antigen in cancer immunotherapy.
Meng X, Sun X, Liu Z, He Y. Meng X, et al. Int Immunopharmacol. 2021 Sep;98:107889. doi: 10.1016/j.intimp.2021.107889. Epub 2021 Jun 24. Int Immunopharmacol. 2021. PMID: 34174699 Free article. Review.
Tumor antigens include tumor-specific antigens and tumor-associated antigens, and they function as targets for immunotherapy, such as cancer vaccines and autologous T cells. Cancer/testis antigens (CTAs), which is a group of …
Tumor antigens include tumor-specific antigens and tumor-associated antigens, and they function as targets for immun
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J. Thomas R, et al. Front Immunol. 2018 May 1;9:947. doi: 10.3389/fimmu.2018.00947. eCollection 2018. Front Immunol. 2018. PMID: 29770138 Free PMC article. Review.
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. ...Cancer treatment has been revolutionized over the last few decades with immunotherapy e …
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expressi …
Progress and challenges of immunotherapy in triple-negative breast cancer.
Zhu Y, Zhu X, Tang C, Guan X, Zhang W. Zhu Y, et al. Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188593. doi: 10.1016/j.bbcan.2021.188593. Epub 2021 Jul 17. Biochim Biophys Acta Rev Cancer. 2021. PMID: 34280474 Review.
Triple-negative breast cancer (TNBC), a subtype of breast cancer, is defined as lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) expression. ...Following the development of immune checkpoint inhibition ( …
Triple-negative breast cancer (TNBC), a subtype of breast cancer, is defined as lacking estrogen receptor (ER), progesterone r …
Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A, Zamani MR, Pourvahedi M, Golchehre Z, Hosseini Bereshneh A, Rezaei N. Salmaninejad A, et al. Immunol Invest. 2016 Oct;45(7):619-40. doi: 10.1080/08820139.2016.1197241. Epub 2016 Sep 7. Immunol Invest. 2016. PMID: 27603913 Review.
Cancer/testis antigens (CTAs) are named based on their expression pattern that is restricted in a number of normal and abnormal tissues. ...ABBREVIATIONS: AIRE: autoimmune regulator; cAMP: cyclic adenosine 3',5'-cyclic monophosphate; CEA: carcinoembryonic
Cancer/testis antigens (CTAs) are named based on their expression pattern that is restricted in a number of normal and
Cancer testis antigen and immunotherapy.
Krishnadas DK, Bai F, Lucas KG. Krishnadas DK, et al. Immunotargets Ther. 2013 Apr 17;2:11-9. doi: 10.2147/ITT.S35570. eCollection 2013. Immunotargets Ther. 2013. PMID: 27471684 Free PMC article. Review.
The identification of cancer testis (CT) antigens has been an important advance in determining potential targets for cancer immunotherapy. ...This review details the expression of melanoma antigen family A, 1 (MAGE-A1), melanoma antige
The identification of cancer testis (CT) antigens has been an important advance in determining potential targets for …
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.
Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, Signoretti S, Liu JS, Liu XS. Li B, et al. Genome Biol. 2016 Aug 22;17(1):174. doi: 10.1186/s13059-016-1028-7. Genome Biol. 2016. PMID: 27549193 Free PMC article.
RESULTS: We analyze tumor-infiltrating immune cells in over 10,000 RNA-seq samples across 23 cancer types from The Cancer Genome Atlas (TCGA). Our computationally inferred immune infiltrates associate much more strongly with patient clinical features, viral infectio …
RESULTS: We analyze tumor-infiltrating immune cells in over 10,000 RNA-seq samples across 23 cancer types from The Cancer Geno …
DNA vaccine for cancer immunotherapy.
Yang B, Jeang J, Yang A, Wu TC, Hung CF. Yang B, et al. Hum Vaccin Immunother. 2014;10(11):3153-64. doi: 10.4161/21645515.2014.980686. Hum Vaccin Immunother. 2014. PMID: 25625927 Free PMC article. Review.
Despite all the practical advantages, DNA vaccines face challenges in inducing potent antigen specific cellular immune responses as a result of immune tolerance against endogenous self-antigens in tumors. Strategies to enhance immunogenicity of DNA vaccines against …
Despite all the practical advantages, DNA vaccines face challenges in inducing potent antigen specific cellular immune responses as a …
Immunotherapy in soft-tissue sarcoma.
Ayodele O, Razak ARA. Ayodele O, et al. Curr Oncol. 2020 Feb;27(Suppl 1):17-23. doi: 10.3747/co.27.5407. Epub 2020 Feb 1. Curr Oncol. 2020. PMID: 32174754 Free PMC article. Review.
In the advanced setting, the role of systemic therapies is modest and is associated with poor survival. With the discovery of immunotherapies in other tumour types such as melanoma and lung cancer, interest has been renewed in exploring immunotherapy in sts. …
In the advanced setting, the role of systemic therapies is modest and is associated with poor survival. With the discovery of immunothera
Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.
Raza A, Merhi M, Inchakalody VP, Krishnankutty R, Relecom A, Uddin S, Dermime S. Raza A, et al. J Transl Med. 2020 Mar 27;18(1):140. doi: 10.1186/s12967-020-02306-y. J Transl Med. 2020. PMID: 32220256 Free PMC article. Review.
Antigenic profiling of cancer tissues and determination of any pre-existing immune responses to cancer antigens may help predict responses to immune intervention in cancer. NY-ESO-1, a cancer testis antigen is the most immun
Antigenic profiling of cancer tissues and determination of any pre-existing immune responses to cancer antigens
The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer.
Xu Y, Zou R, Wang J, Wang ZW, Zhu X. Xu Y, et al. Cell Prolif. 2020 Mar;53(3):e12770. doi: 10.1111/cpr.12770. Epub 2020 Feb 5. Cell Prolif. 2020. PMID: 32022332 Free PMC article. Review.
Preferentially expressed antigen in melanoma (PRAME), which belongs to the cancer/testis antigen (CTA) gene family, plays a pivotal role in multiple cellular processes and immunotherapy response in human cancers. ...Therefore, the modulation of …
Preferentially expressed antigen in melanoma (PRAME), which belongs to the cancer/testis antigen (CTA) gene fami …
1,006 results